UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
UNITY Biotechnology (Nasdaq: UBX) will host an investor call on August 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET, featuring retinal expert Robert Bhisitkul, M.D., Ph.D.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UNITY Biotechnology (Nasdaq: UBX) will host an investor call on August 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET, featuring retinal expert Robert Bhisitkul, M.D., Ph.D. The discussion will center around its lead program, UBX1325, aimed at developing therapies targeting age-related diseases. The call will be accessible via their website, with a replay available shortly after. UNITY is focused on innovative therapeutics to combat aging diseases by eliminating senescent cells, with implications for ophthalmologic and neurologic conditions.
Positive
- Investor call focused on lead program UBX1325 indicates ongoing development and transparency with stakeholders.
- Collaboration with retinal expert Robert Bhisitkul may enhance credibility and insight into the program's potential.
Negative
- None.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was +54.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., to be held on Friday, August 12 at 5:00 a.m. PT/8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325 on Friday, August 12, 2022 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.
The live webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Media Contact:
Evoke Canale
Katherine Smith
Katherine.Smith@evokegroup.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Source: Unity Biotechnology, Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.